CTRI/2022/01/039407已完成2 期
A Randomized Double Blind Placebo Controlled Study Of Celecoxib Add-On In Obsessive Compulsive Disorder
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Informed consent from the patient
- •Diagnosed with OCD (ICD-10 DCR)
- •Symptomatic (Y-BOCS Score more than or equal to 21)
- •Drug naive (Drug free period for at least 12 weeks)
排除标准
- •Any other psychiatric comorbidity(Except nicotine dependence)
- •Any medical condition requiring priority management or where use of COX-2 inhibitors is contraindicated
- •Patient receiving a course of any immunosuppressive therapy or NSAID in adequate
- •dose for consecutive 5 days or more in the past 8 weeks.
- •Established non-response to Fluoxetine (Adequate dose for adequate duration)
- •Intellectual disability (assessed clinically), Pregnancy and breastfeeding
研究者
相似试验
已完成
3 期
Study of Effects of Celecoxib Augmentation of Olanzapine Treatment In Schizophrenia in a Randomized Controlled TrialCTRI/2017/05/008611King Georges Medical University50
进行中（未招募）
1 期
Study of the effects of blocking the enzyme PCSK9 on artery wall inflamatioMedDRA version: 18.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersHypercholesterolemiaEUCTR2015-003731-35-NLAmgen Inc120
Unknown
3 期
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 PneumoniaCOVID19 PneumoniaPACTR202106466447805Genentech Inc379
进行中（未招募）
不适用
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo ParathyroidectomyReduction of hypercalcemia in subjects with primary hyperparathyroidism (HPT) who meet criteria for parathyroidectomy on the basis of corrected total serum calcium, but who are unable to undergo parathyroidectomy.MedDRA version: 12.0Level: LLTClassification code 10036693Term: Primary hyperparathyroidismEUCTR2009-012943-41-PTAmgen Inc160
招募中
1 期
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)Pruritus associated with Primary Sclerosing Cholangitis (PSC)MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805CTIS2023-505764-11-00Mirum Pharmaceuticals Inc.395